Product Description
The research-grade biosimilar is a bispecific T-cell engager monoclonal antibody that targets both CD19 and CD3?. A single molecule of this antibody possesses two binding sites: one for CD3? expressed on T-cells and second for CD19 expressed on B-cells. The antibody forms a synapse between T-cells and malignant B-cells. Upon interaction, T-cells are activated, which release cytotoxic granules such as perforins and granzymes. Granzymes enter the cell cytoplasm with the help of perforins and initiate cell death pathways via activation of caspases. The original antibody has been approved by the FDA to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in both adults and children
Biovision | A2225 | Anti-CD19/CD3? (Blinatumomab), Bispecific Antibody DataSheet
Antibody Target: CD19/CD3?
Target Alternative Name: AMG103, BITE MT-103, MEDI-538, MT103, bscCD19xCD3, MEDI 538, MEDI538, MT 103, B4, CVID3, CD19, T3E, TCRE, IMD18, CD3E
Tag Line: The biosimilar is a bispecific monoclonal antibody that targets both CD19 on malignant B cells and CD3? on T-cells and causes caspase-mediated cell death. The original monoclonal antibody is approved to treat acute lymphoblastic leukemia
Category: Biosimilars
Host: Recombinant
Isotype: (scFv-kappa-heavy)-(scFv-heavy-kappa)
Species Reactivities: Human
Immunogen Sequence: Human CD19/CD3?
Accession #: DB09052
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE